In the following video, Motley Fool health-care analyst David Williamson discusses some very surprising trial results from Amgen . The company has announced phase 3 results that it has bioengineered a version of the herpes virus to attack melanoma, by singling out only fast-dividing cells. David tells us the possible ramifications both for investors and for patients.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report " 3 Stocks That Will Help You Retire Rich " names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Why Melanoma Should Fear Herpes originally appeared on Fool.com.David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.